Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system

BMC Complementary and Alternative Medicine

Limin Hu¹  Bin Yu¹  Qingqing Liu¹  Meijiao Li¹  Fang Shi¹  Hong Guo¹ 

[1] Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, #312 Anshan Xi Road, Nankai District, Tianjin 300193, China

关键词: Ubiquitin-proteasome system;    Parkinson’s disease;    Eucommia ulmoides;   

Others  :  1199168
DOI  :  10.1186/s12906-015-0675-7

 received in 2014-09-16, accepted in 2015-05-13,  发布年份 2015

【 摘 要 】

Background

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by a loss of dopaminergic neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. The purpose of this study was to investigate potential in vivo protective effects of Duzhong against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), as well as the bioactive constituents against 1-methyl-4-phenylpyridinium (MPP⁺) toxicity in vitro.

Methods

Male C57BL/6 mice were intraperitoneally administrated five consecutive injections of MPTP every 24 h at a dose of 30 mg/kg to induce an in vivo PD model. Pole and traction tests were performed in mice to evaluate motor deficits and bradykinesia after the final MPTP administration. The striatal levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid and homovanilic acid, were measured using a High-performance liquid chromatography-electrical conductivity detector. To further explore the bioactive constituents and protective mechanisms of Duzhong, seven compounds from Duzhong were tested on MPP⁺-treated SH-SY5Y cell lines in vitro. A proteasome enzymatic assay and Cell Counting Kit-8 were performed to examine proteasomal activity and cell viability of Duzhong-treated cells, respectively, after exposure to MPP⁺ and proteasome inhibitor MG132.

Results

Duzhong antagonized the loss of striatal neurotransmitters and relieved the associated anomaly in ambulatory locomotor activity in PD mice after a 3-day pre-treatment of Duzhong crude extract. The five Duzhong compounds attenuated MPP⁺-induced dysfunction of protease activity and reduced MG132-induced cytotoxicity.

Conclusion

Duzhong could serve as a potential candidate for PD treatment, and its mechanism involves the amelioration of the ubiquitin-proteasome system.

【 授权许可】

   
2015 Guo et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res. 2009; 34:55-65.
• [2]Inzelberg R, Schechtman E, Hocherman S. Visuo-motor coordination deficits and motor impairments in Parkinson's disease. PLoS One. 2008; 3: Article ID e3663
• [3]Kremens D, Hauser RA, Dorsey ER. An update on Parkinson's disease: improving patient outcomes. Am J Med. 2014; 127:S3.
• [4]Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999; 22:123-44.
• [5]Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005; 28:57-87.
• [6]Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet. 2005; 14:2749-55.
• [7]Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al.. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392:605-8.
• [8]Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al.. The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395:451-2.
• [9]Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S et al.. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000; 25:302-5.
• [10]Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82:373-428.
• [11]Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002; 111:209-18.
• [12]Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H et al.. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet. 2003; 12:1945-58.
• [13]Camicioli R, Grossmann SJ, Spencer PS, Hudnell K, Anger WK. Discriminating mild parkinsonism: methods for epidemiological research. Mov Disord. 2001; 16:33-40.
• [14]Ebadi M, Govitrapong P, Sharma S, Muralikrishnan D, Shavali S, Pellett L et al.. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease. Biol Signals Recept. 2001; 10:224-53.
• [15]Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp. 1999; 66:85-97.
• [16]Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP, Tuttle JB. Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res. 2001; 891:94-105.
• [17]Kumar H, More SV, Han SD, Choi JY, Choi DK. Promising therapeutics with natural bioactive compounds for improving learning and memory–a review of randomized trials. Molecules. 2012; 17:10503-39.
• [18]Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm. 2011; 118:1661-90.
• [19]Prashanth LK, Fox S, Meissner WG. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol. 2011; 98:31-54.
• [20]Deyama T, Nishibe S, Nakazawa Y. Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacol Sin. 2001; 22:1057-70.
• [21]Kwan CY, Chen CX, Deyama T, Nishibe S. Endothelium-dependent vasorelaxant effects of the aqueous extracts of the Eucommia ulmoides Oliv. leaf and bark: implications on their antihypertensive action. Vascul Pharmacol. 2003; 40:229-35.
• [22]Kwon SH, Kim MJ, Ma SX, You IJ, Hwang JY, Oh JH et al.. Eucommia ulmoides Oliv. Bark. protects against hydrogen peroxide-induced neuronal cell death in SH-SY5Y cells. J Ethnopharmacol. 2012; 142:337-45.
• [23]Zhou Y, Liang M, Li W, Li K, Li P, Hu Y et al.. Protective effects of Eucommia ulmoides Oliv. bark and leaf on amyloid β-induced cytotoxicity. Environ Toxicol Pharmacol. 2009; 28:342-9.
• [24]Kwon SH, Lee HK, Kim JA, Hong SI, Kim SY, Jo TH et al.. Neuroprotective effects of Eucommia ulmoides Oliv. Bark on amyloid beta(25–35)-induced learning and memory impairments in mice. Neurosci Lett. 2011; 487:123-7.
• [25]Kwon SH, Ma SX, Hong SI, Kim SY, Lee SY, Jang CG. Eucommia ulmoides Oliv. bark. attenuates 6-hydroxydopamine-induced neuronal cell death through inhibition of oxidative stress in SH-SY5Y cells. J Ethnopharmacol. 2014; 152:173-82.
• [26]Kwon SH, Ma SX, Joo HJ, Lee SY, Jang CG. Inhibitory Effects of Eucommia ulmoides Oliv. Bark on Scopolamine-Induced Learning and Memory Deficits in Mice. Biomol Ther (Seoul). 2013; 21:462-9.
• [27]Yin ZH. Eucommia phytoestrogens active ingredient research. China University of Petroleum, Master thesis; 2010.
• [28]Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol. 1985; 50:435-41.
• [29]Doyle SE, Grace MS, McIvor W, Menaker M. Circadian rhythms of dopamine in mouse retina: the role of melatonin. Vis Neurosci. 2002; 19:593-601.
• [30]Cheng YF, Zhu GQ, Wang M, Cheng H, Zhou A, Wang N et al.. Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis. Neurosci Res. 2009; 63:52-8.
• [31]Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci. 2013; 36:543-54.
• [32]Lau YS, Patki G, Das-Panja K, Le WD, Ahmad SO. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur J Neurosci. 2011; 33:1264-74.
• [33]Lim KL. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Expert Rev Proteomics. 2007; 4:769-81.
• [34]Le Couteur DG, Muller M, Yang MC, Mellick GD, McLean AJ. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev Environ Health. 2002; 17:51-64.
• [35]Chai X, Wang Y, Su Y, Bah AJ, Hu L, Gao Y et al.. A rapid ultra performance liquid chromatography–tandem mass spectrometric method for the qualitative and quantitative analysis of ten compounds in Eucommia ulmodies Oliv. J Pharm Biomed Anal. 2012; 57:52-61.